Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

被引：0
|
作者：
Barr, Hallie
Dempsey, Jessica
Waller, Allyson
Huang, Ying
Williams, Nita
Sharma, Nidhi
Benson, Don M., Jr.
Rosko, Ashley E.
Efebera, Yvonne A.
Hofmeister, Craig C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1889
引用
收藏
页数：3
相关论文
共 50 条
  • [41] An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
    Paul, Barry
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Hamadeh, Issam
    Usmani, Saad Z.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 795 - 802
  • [42] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2017, 77 : 2013 - 2024
  • [43] Infectious and immunological sequelae of daratumumab in multiple myeloma
    Johnsrud, Andrew J.
    Johnsrud, Joyce J.
    Susanibar, Sandra A.
    Kamimoto, Jorge J.
    Kothari, Atul
    Burgess, Mary
    Van Rhee, Frits
    Rico, Juan C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) : 187 - 189
  • [44] Subcutaneous versus intravenous daratumumab in multiple myeloma
    Shibusawa, Motoharu
    Tanimoto, Tetsuya
    LANCET HAEMATOLOGY, 2020, 7 (08): : E558 - E558
  • [45] A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting
    Geirnaert, Marc
    Howarth, Jacy
    Martin, Kristen
    Ricard, Chad
    Streilein, Scott
    Wasney, Danica
    Dao, Vi
    Kotb, Rami
    Rimmer, Emily
    Minuk, Leonard
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (04) : 907 - 910
  • [46] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    DRUGS, 2017, 77 (18) : 2013 - 2024
  • [47] Potential role of daratumumab in the treatment of multiple myeloma
    Khagi, Yulian
    Mark, Tomer M.
    ONCOTARGETS AND THERAPY, 2014, 7 : 1095 - 1100
  • [48] Mechanisms of resistance to daratumumab in patients with multiple myeloma
    Iversen, Katrine Fladeland
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024,
  • [49] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Boccadoro, Mario
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Sureda Balari, Anna
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Silzle, Tobias
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Ahmadi, Tahamtan
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Rodriguez-Otero, Paula
    Blade, Joan
    Moreau, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04): : 301 - 313
  • [50] Multiple Myeloma Combination with Daratumumab prolongs Survival
    Krome, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (23) : 1672 - 1672
12345